{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:24:40Z","timestamp":1781843080477,"version":"3.54.5"},"reference-count":55,"publisher":"Informa UK Limited","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.4155\/fmc.11.96","type":"journal-article","created":{"date-parts":[[2011,9,23]],"date-time":"2011-09-23T13:25:12Z","timestamp":1316784312000},"page":"1635-1645","source":"Crossref","is-referenced-by-count":19,"title":["What is the Potential for Inhaled P38 Inhibitors in the Treatment of Chronic Obstructive Pulmonary Disease?"],"prefix":"10.1080","volume":"3","author":[{"given":"David S","family":"Millan","sequence":"first","affiliation":[{"name":"Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent, CT13 9NJ, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2011,9,23]]},"reference":[{"key":"e_1_3_3_3_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61380-4"},{"key":"e_1_3_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.16125_2"},{"key":"e_1_3_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60326-3"},{"key":"e_1_3_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2008.03.001"},{"key":"e_1_3_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/372739a0"},{"key":"e_1_3_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074278"},{"key":"e_1_3_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6942(03)00048-2"},{"key":"e_1_3_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9012906"},{"key":"e_1_3_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026054985885"},{"key":"e_1_3_3_3_10_1","unstructured":"Vertex Pharmaceuticals Inc. Vertex moves to re-allocate resources from VX-745 in p38 MAP kinase program to accelerate development of second generation drug candidates VX-702 and VX-850. Press Release 24September2001."},{"key":"e_1_3_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24266"},{"key":"e_1_3_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104802"},{"key":"e_1_3_3_3_13_1","unstructured":"Genovese MC CohenSB WofsyDet al. A randomized double-blind placebo-controlled phase 2 study of an oral p38\u03b1 MAPK inhibitor SCIO-469 in patients with active rheumatoid arthritis. Presented at: The American College of Rheumatology Scientifc Meeting. San Francisco CA USA (2008) (Abstract 715)."},{"key":"e_1_3_3_3_14_1","unstructured":"Wang J KaulS CampanhaHet al. Multiple ascending dose study of a potent p38 MAPK inhibitor BMS-582949 in subjects with stable RA receiving concomitant methotrexate. Presented at: The American College of Rheumatology Scientifc Meeting. San Francisco CA USA (2008) (Abstract 356)."},{"key":"e_1_3_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24485"},{"key":"e_1_3_3_3_16_1","unstructured":"Array Biopharma Inc. Array BioPharma Announces Top-Line Results in Two Phase I Clinical Trials. Press Release 8July2009."},{"key":"e_1_3_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24264"},{"key":"e_1_3_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.171"},{"key":"e_1_3_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.11.013"},{"key":"e_1_3_3_3_20_1","first-page":"PI","article-title":"SCIO-469, a novel p38 alpha MAPK inhibitor provides efficacy in acute post-surgical dental pain.","volume":"75","author":"Tong SE","year":"2004","unstructured":"Tong SE , DanielsSE, MontanoTet al. SCIO-469, a novel p38 alpha MAPK inhibitor provides efficacy in acute post-surgical dental pain. Am. Soc. Clin. Pharmacol. Ther. 75, PI\u20131 (2004).","journal-title":"Am. Soc. Clin. Pharmacol. Ther."},{"key":"e_1_3_3_3_21_1","unstructured":"Remmers A . p38 Inhibitors as new therapies for inflammatory pain: ARRY-797. Presented at: The Arrowhead Pain Therapeutic Summit. New Brunswick NJ USA 6 October 2008."},{"key":"e_1_3_3_3_22_1","unstructured":"Remmers A YatesJ DanielsSet al. A novel p38\u03b1 inhibitor ARRY-797 provides significant analgesic benefit following third molar extraction. Presented at: The American Pain Society\u2019s Annual Scientific Meeting. Tampa FL USA 8\u201310 May 2008."},{"key":"e_1_3_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3580.3580"},{"key":"e_1_3_3_3_24_1","unstructured":"Winski SL FreemanBB RemmersAEet al. ARRY-614 an inhibitor of p38 MAP kinase and angiogenic targets is active in preclinical models of hematological malignancies and significantly reduces ex-vivo cytokine production in normal human subjects. Presented at: The 7th International Symposium on Targeted Anti-Cancer Therapeutics. Amsterdam The Netherlands 23\u201325 March 2009."},{"key":"e_1_3_3_3_25_1","volume-title":"European Society of Cardiology\u2019s Acute Cardiac Care Symposium","author":"Vertex Pharmaceuticals Inc.","year":"2004","unstructured":"Vertex Pharmaceuticals Inc. Preliminary Phase IIa data for VX-702 demonstrate tolerability and reduction in C-reactive protein in cardiovascular patients. Presented at: European Society of Cardiology\u2019s Acute Cardiac Care Symposium. Rome, Italy, 17\u201320October2004."},{"key":"e_1_3_3_3_26_1","unstructured":"MacNee W AllanR JonesIet al. A randomised placebo controlled trial of 6 weeks treatment with a novel oral p38 inhibitor in patients with COPD. Presented at: The European Respiratory Society Meeting. Barcelona Spain 18\u201322 September 2010."},{"key":"e_1_3_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00036707"},{"key":"e_1_3_3_3_28_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(24)39230-4","article-title":"SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.","volume":"293","author":"Underwood DC","year":"2000","unstructured":"Underwood DC , OsbornRR, KotzerCJet al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. Pharmacol. Exp. Ther. 293, 281\u2013288 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.127092"},{"key":"e_1_3_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200408-1006OC"},{"key":"e_1_3_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.10.1411"},{"key":"e_1_3_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.3.9608058"},{"key":"e_1_3_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm1005989"},{"key":"e_1_3_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/jam.2006.19.47"},{"key":"e_1_3_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2153"},{"key":"e_1_3_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01493.x"},{"key":"e_1_3_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043455729"},{"key":"e_1_3_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2007.08.005"},{"key":"e_1_3_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10386"},{"key":"e_1_3_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/1061186031000086117"},{"key":"e_1_3_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(03)00656-5"},{"key":"e_1_3_3_3_42_1","unstructured":"Edsb\u00e4cker S . Uptake retention and biotransformation of corticosteroids in the lung and airways. In: Inhaled Steroids in Asthma: Optimizing Effects in the Airways. Schleimer RP O\u2018Byrne PMO Szefler SJ Brattsand R (Eds). Marcel Dekker NY USA 213\u2013246 (2002)."},{"key":"e_1_3_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm000407e"},{"key":"e_1_3_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-120000653"},{"key":"e_1_3_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60926-9"},{"key":"e_1_3_3_3_46_1","unstructured":"Millan D BunnageM ButcherKet al. First disclosure of PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease. Presented at: 240th ACS National Meeting. Boston MA USA 22\u201326 August 2010."},{"key":"e_1_3_3_4_2_1","unstructured":"Pulmagen Therapeutics (Inflammation) Ltd: WO131030 (2010)."},{"key":"e_1_3_3_4_3_1","unstructured":"Pulmagen Therapeutics (Inflammation) Ltd: WO094956 (2010)."},{"key":"e_1_3_3_4_4_1","unstructured":"Pulmagen Therapeutics (Inflammation) Ltd: WO094955 (2010)."},{"key":"e_1_3_3_4_5_1","unstructured":"Mathias JP Millan DS Lewthwaite RA et al. US0035922 (2006)."},{"key":"e_1_3_3_5_2_1","unstructured":"ClinicalTrials. http:\/\/www.clinicaltrials.gov (Accessed 13April2011)"},{"key":"e_1_3_3_5_3_1","unstructured":"Array BioPharma Inc. www.arraybiopharma.com (Accessed 13April2011)"},{"key":"e_1_3_3_5_4_1","unstructured":"US FDA. Dose values taken from the respective drug labels. www.fda.gov (Accessed 14April2011)"},{"key":"e_1_3_3_5_5_1","unstructured":"GlaxoSmithKline. www.gsk.com (Accessed 14April2011)"},{"key":"e_1_3_3_5_6_1","unstructured":"Pfizer. www.pfizer.com (Accessed 14April2011)"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.11.96","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T21:28:28Z","timestamp":1741728508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.11.96"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,23]]},"references-count":55,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.4155\/fmc.11.96"],"URL":"https:\/\/doi.org\/10.4155\/fmc.11.96","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,23]]}}}